The Health Equation
Refuse to Choose: nutrition for performance and a longer life
June 17, 2026 · 12 min
The Performance and Longevity Series, No.01
A current synthesis of post-2023 trials, meta-analyses, and consensus statements, translated into a periodized field manual. The discipline that forges the body is the discipline that scales the company. Built on evidence, not affirmations.
A note before you read
The question is not performance or longevity
The standard framing forces a false choice. Train hard, eat for power, and burn the candle, or eat lean, hold back, and protect the long run. This brief tests that premise against the current evidence and finds it wanting.
The central insight runs through every section that follows: an exercising masters athlete occupies a physiologically distinct category from the sedentary midlife population that most longevity cautions were built on. Exercise-mediated protection, through IGFBP-3 elevation, immune cancer surveillance, telomere preservation, and epigenetic aging deceleration, is large, consistent, and absent from cohort data drawn on mostly inactive people.
The verdict, up front
For a trained adult at masters age, performance and longevity goals are largely aligned. The apparent tension dissolves once macronutrient targets are periodized across training phases. The conflict is structural, not unavoidable.
The quantified case
The data is not subtle
The belief that high caloric throughput from elite endurance training shortens life has a theoretical basis in the rate-of-living hypothesis. Across multiple large cohorts, the empirical record points the opposite way.
Read this twice
High caloric throughput via endurance training does not shorten human lifespan. It substantially extends it. Any diet that degrades training quality risks the primary longevity mechanism: a high VO2max held through consistent work.
Sources: Marijon 2013, French TdF cyclists; Runacres systematic review, n=165,033; Garatachea meta-analysis, n>42,000.
01 . The mechanistic foundation
Same engine, two outputs
mTOR, IGF-1, autophagy, and inflammation sit at the center of the performance-longevity question. Understanding the biology is what turns a false choice into a periodized plan.
IGF-1: lower is not better, the curve is U-shaped
An older literature read IGF-1 and mortality as a straight line: more protein, more IGF-1, more risk. The dominant current picture, drawn from large prospective cohorts, is fundamentally different. Below the band, low IGF-1 carries a hazard ratio of 1.33 and independently predicts frailty and sarcopenia at masters age. Above the band, the upper-tertile signal is real but context-dependent, and exercise raises IGFBP-3, which binds free IGF-1 and blunts oncogenic signaling in trained athletes.
The operating target
Hold IGF-1 in the 120 to 180 ng/mL band during the performance phase and allow it to cycle lower during base and off-season. Treat this as prudent risk-mitigation, not a lower-is-better directive.
Sources: Rahmani et al. 2022, 19-cohort meta-analysis; EPIC-Heidelberg, JCEM 2023; exercise and IGF-1 meta-analysis, 2025.
02 . Protein, the highest-leverage lever
At 70+, the caution reverses
Protein is the most practically impactful nutritional variable, and the one where age flips the recommendation. The Levine 2014 signal, higher mortality with high protein at 50 to 65, was drawn from a mostly sedentary cohort, and exercise attenuates it by an estimated 60 to 90% through IGFBP-3 elevation and immune surveillance. Past 70, higher protein becomes net protective. What protects a 70-year-old is not what a longevity caution for the sedentary would predict.
| Context | Target (g/kg/day) | Grade |
|---|---|---|
| Endurance athlete, heavy training | 1.4 to 1.7 | A |
| Strength / power, heavy training | 1.6 to 2.0 | A |
| Base / off-season, masters 50+ | 1.2 to 1.4 | Moderate |
| Very old, 85+ | 1.4 to 1.7 | B |
The periodized rule
Run 1.6 to 2.0 g/kg through peak training, then moderate to 1.2 to 1.4 g/kg with plant emphasis in base phases to open IGF-1 cycling windows. For athletes 70+, drop the moderation: sarcopenia prevention dominates.
Sources: ISSN Position Stand (Morton 1.62 breakpoint); Campbell et al. 2023; protein and healthy aging, 2025.
03 . Carbohydrate, fuel the work
Fuel scales with a trained gut
Carbohydrate intake during racing is dose-responsive to event duration and, critically, to gut training. The 90 g/hour gate is the line beyond which deliberate gut conditioning is required to avoid distress. Elite, gut-trained athletes reach 90 to 120 g/hour; age-groupers run 60 to 90. The extra 30 g requires weeks of deliberate training, not a race-day decision.
Refuse the dogma
Carbohydrate periodization beats chronic restriction. Fuel high for hard sessions and racing; use selective train-low work for adaptation, never as a longevity strategy in itself. NHANES analysis links the lowest-carbohydrate quartile to +5.65 years of biological age, and zero RCT evidence supports keto for athlete longevity.
Sources: IOC carbohydrate-during-exercise consensus; gut-training oxidation literature; NHANES low-carbohydrate biological-age analysis, 2023 to 2025.
More is not always safer: fats, omega-3, and plant bioactives
Omega-3 and dietary nitrate both reward a target zone rather than a maximum. Push past it and the benefit plateaus or, with omega-3 and atrial fibrillation, reverses. Target an Omega-3 Index of 8% or higher: beyond 1.5 g/day EPA and DHA, atrial fibrillation odds climb. Source matters for nitrate too: plant-sourced carries a hazard ratio of 0.83, animal-sourced 1.09, and additive-permitted meat nitrate 1.19. The molecule is identical; the matrix is not.
Sources: omega-3 dose and atrial fibrillation pooled analyses; Danish cohort nitrate-by-source, n=52,247, 27-year follow-up.
04 . The female athlete branch
Protect availability first
Most dose-response data was generated in young men. The female athlete branch corrects for energy availability, the menstrual and menopausal transitions, and iron status, variables that change the targets. Low energy availability is the upstream risk that propagates into bone, endocrine, and cardiovascular harm. For the female masters athlete, the first nutritional duty is keeping availability above the threshold, then meeting elevated protein needs through the menopausal transition.
The honest gap
No RCT of menopausal hormone therapy plus structured athletic training plus nutritional manipulation in masters female athletes exists. Where data are absent, that absence is stated, not papered over.
Sources: IOC 2023 REDs consensus; female athlete energy-availability and bone literature; ferritin and endurance-performance thresholds.
05 . Biomarkers, the feedback loop
The instruments on the dashboard
Population averages do not predict an individual. Six markers convert general recommendations into a calibrated practice, revealing exactly where one athlete deviates from the cohort mean. Tracked together and re-checked through the season, they turn the periodization framework from a static prescription into a responsive system.
| Biomarker | Target | What it tells you |
|---|---|---|
| IGF-1 | 120 to 180 ng/mL build; <160 base | Anabolic drive vs U-shaped mortality balance |
| hs-CRP | <1.0 mg/L | Chronic inflammation; sample 48 to 72h post-hard session |
| Omega-3 Index | 8% or higher | Membrane EPA and DHA; cardiac and recovery status |
| VO2max | Stable or rising | Strongest single objective longevity predictor |
| DXA / BMD | Lean mass and bone trend | Sarcopenia and bone-health trajectory |
| Epigenetic age (DunedinPACE) | <1.0 | Pace of biological aging, the speedometer |
One measurement note
Never read hs-CRP within 48 to 72 hours of a hard session. Transient exercise-induced elevation is adaptive and will mislead clinical interpretation. Timing is part of the measurement.
Sources: Lancet eBioMedicine 2025, hs-CRP 20-year follow-up; CALERIE-2 DunedinPACE calibration; DNAmFitAge VO2max coupling.
The periodization framework
One framework, four phases
The whole argument resolves into a single operating table. Macronutrient targets and emphasis shift across the training year, capturing the performance signal in peak phases and the longevity windows in base.
| Base / Recovery | Build | Intensity / Peak | Race Week | |
|---|---|---|---|---|
| Protein g/kg | 1.2 to 1.4 | 1.4 to 1.7 | 1.6 to 2.0 | 1.6 to 2.0 |
| Carb g/kg | 3 to 5 | 6 to 8 | 7 to 10 | 10 to 12 |
| Emphasis | Longevity | Balanced | Performance | Performance |
The rule that ties it together
Hold protein 1.4 to 2.0 g/kg year-round as the working band, then move within it by phase. Match mTOR activation to training demand instead of chronically suppressing or maximizing it. Masters 70+: no base-phase protein restriction, hold 1.4 to 2.0 g/kg year-round.
Sources: ISSN Position Stands; GSSI/Moore 2024 endurance protein ranges; periodization synthesis across the underlying evidence base.
Guardrails . the safe-zone hierarchy
Certain, prudent, or unproven
Not every practice carries equal evidence. Sorting the longevity toolkit into three tiers, from settled to speculative, keeps the plan honest and prevents an appealing theory from displacing a proven one.
Tier 1, certain benefit: do these without hesitation
Maintain VO2max through structured aerobic work; resistance train 2 or more times weekly; hold hs-CRP under 1.0 mg/L; reach an Omega-3 Index of 8% or higher; keep vitamin D 40 to 60 ng/mL and ferritin 50 to 100 ng/mL; sleep 7 to 9 hours.
Tier 2, prudent and evidence-informed: adopt with monitoring
Periodize protein (1.6 to 2.0 peak, 1.2 to 1.4 base); enrich with 30 to 40% plant protein; allow a 10 to 12 hour eating window most nights; eat leafy greens daily; track IGF-1, DXA, and VO2max annually.
Tier 3, unproven in athletes: approach with caution
Chronic low-carb high-fat for longevity; aggressive caloric restriction during heavy training; omega-3 above 3 g/day without cardiac assessment; extreme train-low without bone monitoring; targeting IGF-1 below 100 ng/mL, the frailty zone at masters age.
The discipline
When a Tier 3 theory is appealing but a Tier 1 practice is proven, the proven practice wins. Learning the hard way is optional when the evidence already exists.
The bottom line
Scale the company. Forge the body. Refuse to choose.
- The trade-off is navigable, not existential. Periodize macronutrient targets across training phases and the apparent conflict dissolves.
- VO2max is the primary longevity imperative. No diet that degrades training quality is worth its theoretical longevity gain.
- Age and sex move the targets. The 70+ protein flip and the female-athlete branch are not footnotes; they change the prescription.
- Measure six markers and let them steer. Population averages do not predict an individual; the dashboard does.
The science does not justify abandoning high-protein performance phases out of longevity caution. It justifies periodizing intelligently and protecting the training stimulus that underpins the entire advantage.
Colophon and method
Method: a synthesis of post-2023 peer-reviewed literature anchored against foundational pre-2023 sources, prioritizing systematic reviews, meta-analyses, RCTs, and IOC, ACSM, and ISSN consensus statements. Mechanistic and animal evidence is flagged as distinct from human outcome evidence. Where data are absent, that absence is stated. Population-level data do not predict individual outcomes; implementation should involve a sports dietitian or sports-medicine physician familiar with masters-athlete physiology.
Selected sources: Marijon et al. 2013 (acc.org); Runacres systematic review (PMC7846545); Garatachea meta-analysis (PubMed 25128074); Rahmani et al. 2022 (PMC8844108); EPIC-Heidelberg, JCEM 2023 (academic.oup.com); ISSN Position Stand (PMC5867436); CALERIE-2, Nature Aging 2023 (nature.com); Masters athletes, Frontiers Immunology 2025 (frontiersin.org); hs-CRP 20-year follow-up, Lancet eBioMedicine 2025 (thelancet.com); Olympic champions, epigenetic aging 2024 (PMC11978583).
Want the room where this gets put into practice?